EUCTR2007-005352-17-DE进行中（未招募）不适用
A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia - Apa-AD
niversity Bonn0 个研究点开始时间: 2009年8月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Key inclusion criteria:
- •Mild to moderate Alzheimer’s dementia, male and femal(NINCDS/ADRDA criteria)
- •Presence of clinically relevant apathy defined by the Neuropsychiatric
- •Inventory (NPI) apathy item (score of >/= 4 points) and the Marin/Starkstein criteria for apathy
- •MMSE: 10-25
- •Age: 55-90
- •Outpatient status, not institutionalized
- •Presence of reliable caregiver
- •Stable treatment with antidementia drugs for at least three months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 220
排除标准
- •Key exclusion criteria:
- •Presence of a clinically relevant depressed mood defined by either the NPI depression item (score >/= 4 points) or DSM-IV criteria for major depressive episode (with depressed mood)
- •Treatment with antipsychotics (may interfere with the Bupropion
- •mechanism of action)
- •Treatment with antidepressants (may interfere with the Bupropion
- •mechanisms of action)
- •Treatment with dopaminergic agents (may interfere with the Bupropion mechanism of action)
- •Treatment with MAO inhibitor (Bupropion contraindication)
- •Other contraindications to Bupropion treatment
研究者
相似试验
进行中（未招募）
不适用
An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of three fixed doses of SSR411298 (10, 50, or 200mg daily) in elderly patients with Major Depressive DisorderMedDRA version: 11.0Level: LLTClassification code 10025453Term: <Manually entered code. Term in E.1.1>Major Depressive DisorderEUCTR2008-001718-26-SKSanofi-Aventis Recherche & Développement500
进行中（未招募）
不适用
Efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-005673-23-GRovartis Pharma Service AG450
进行中（未招募）
不适用
Efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-005673-23-IEovartis Pharma Service AG450
进行中（未招募）
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetesType II DiabetesMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009888-60-BEovartis Pharma Services AG720
进行中（未招募）
不适用
A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 10, 15 and 20 mg) or sitagliptin 100 mg on a background therapy of metformin in obese patients with type 2 diabetesType II DiabetesMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2009-009888-60-DEovartis Pharma Services AG720